1. Scrip
  2. >>Business
  3. >>Strategy

Medical Aesthetics: Sales Rise For Popular Products, But Unmet Needs Remain

 
• By Mandy Jackson

Botox was a game-changer, which means challengers to Allergan's blockbuster are on the way. Dermal fillers and devices also have an important role, but dermatologists say innovation is needed to fill treatment gaps. Business development is ongoing to expand companies' product portfolios.

face elderly woman forehead wrinkles before and after cosmetic procedures
Neurotoxins filled the forehead wrinkle niche, but unmet needs remain, including undereye bags. • Source: Shutterstock

Every big success in the biopharmaceutical industry ends up with competitors looking to develop their own versions of a blockbuster drug, and the medical aesthetics arena is no different with multiple challengers approved or on the way for Allergan PLC's Botox (onabotulinumtoxinA).

Aesthetics Market Review

This article is the third in a series of three about the medical aesthetics market. Part 1 covered the key players in this area while the second part looked at

Botox generated $3.17bn in 2017 sales across its aesthetic and therapeutic indications, and with $1.75bn in sales during the first half of 2018 the product is on track to significantly beat last year's total. Two additional neurotoxins already are on the market with wrinkle-reducing indications and developers of at least two more expect to seek US FDA approval in 2019 and 2020

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

More from Business

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.